Capricor Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CAPR | SLDB | SRPT | RGNX | FDMT | RCKT | |
|---|---|---|---|---|---|---|
| Market cap | 518.60M | 699.11M | 2.01B | 508.96M | 678.40M | 286.51M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -6.1 | -3.8 | 7.8 | -2.6 | -3.0 | -1.6 |
| Price/book | 2.1 | 2.9 | 1.3 | 5.8 | 1.7 | 0.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +32.48% | +54.69% | +7.65% | −30.98% | +12.45% | −19.20% |
| Today | +8.25% | +3.82% | +2.43% | +1.05% | +2.76% | +3.98% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CAPR news ›TENX Investors Have Opportunity to Lead Tenax Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Nov. 2, 2026 /PRNewswire/ -- 2, 2026 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities ofà Tenax Therapeutics, Inc (NASDAQ: TENX)…
Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)
The FDA cited mouse toxicity findings and insufficient pharmacokinetic and juvenile-toxicity data when it placed Bright Minds' planned Phase 2 BMB-101 epilepsy trial on partial clinical hold. An investigation is underway on behalf of DRUG…
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy
Capricor Therapeutics (CAPR) drew investor attention on Wednesday, after the biotech firm presented data from its Phase 3 HOPE-3 trial of Deramiocel for Duchenne Muscular Dystrophy (DMD) at the American Academy of Neurology 2026 Annual…
CAFC Reverses $9.1 Billion Exceptionality Award, Holding Myriad Did Not Foreclose Patent Owner’s 101 Argument
6 hours ago 1 The U.S. Court of Appeals for the Federal Circuit (CAFC) on Friday reversed a district court’s award of attorneys’ fees to Elysium Health, Inc., holding that the lower court erred in assessing the substantive strength of…
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Value Benchmark
Fate Therapeutics, Inc. dropped from Russell 2000 Value Benchmark... Biotechnology & Medical Research Fate Therapeutics, Inc.(NasdaqGM:FATE) dropped from Russell 2000 Value Benchmark
Fate Therapeutics (FATE) Securities Case Faces Another Motion to Dismiss After 2025 Dismissal Order
The case concerns Fate’s collaboration with Janssen Pharmaceuticals. In the complaint addressed by the September 2025 ruling, the remaining falsity theory centered on four statements made in 2022 that allegedly failed to disclose Janssen’s…
ProQR Therapeutics (NASDAQ:PRQR) & Capricor Therapeutics (NASDAQ:CAPR) Head-To-Head Contrast
Posted by Mitch Edgeman on Oct 26th, 2026 ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
Fifth Circuit Vacates Class Certification in Filana Therapeutics Securities Case
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Fifth Circuit Vacates Class Certification in Filana Therapeutics…
CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears
Shares of Capricor Therapeutics (CAPR) fell 11% on Wednesday, extending weeks of decline, as investors weighed the odds of an approval from the U.S. Food and Drug Administration for the company’s lead therapy Deramiocel. The FDA is slated…
Chanel sells majority Capsum stake to Motion Equity Partners
Innovation and manufacturing partner Capsum is now under Motion Equity Partners, with luxury brand and long term partner Chanel remaining a minority shareholder in the company Chanel has sold its majority stake in innovation and…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com5
- globenewswire.com4
- tradingview.com4
- natlawreview.com3
- pluang.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 68 articles, not a forecast.